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Abstract We present experimental evidence that a complex 
made of a double long chain cationic amphiphile and recombinant 
mRNA facilitates the entry and expression of genetic material 
into cells. Combining the properties of the self replicating recom- 
binant mRNA driven by the Semliki Forest Virus (SFV) replicon 
and the transfection potentialities of a new cationic amphiphile 
(N-t-butyl-N'-tetradecyl-3-tetradecylaminopropionamidine) yields a 
highly efficient mRNA transfection system conferring up to 100% 
infectivity. The preparation and characterization of the long chain 
amidine cationic amphiphile-mRNA complex as well as the influ- 
ence of the diC14-amidinelRNA ratio on the infective activity are 
described. 
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1. Introduction 
Positively charged liposomes have been described to associ- 
ate spontaneously with DNA [1-9] and RNA [10,11] and facil- 
itate its entry and expression into eukaryotic cells. In vivo 
applications are being developed and some of them are promis- 
ing for gene therapy [12-20]. 
RNA transfection can be an alternative to the use of DNA. 
Indeed, mRNA can be translated to corresponding proteins in 
virtually all eukaryotic ells without integrating into the host 
genome, thus offering a safe way for in vivo gene transfer. 
Nevertheless, mRNA is most sensitive to degradation and will 
not be replicated in the cell. This limitation has been shown to 
be alleviated by using self replicating recombinant mRNA 
driven by the Semliki-Forest Virus (SFV) replicon [21]. In this 
system, a DNA sequence coding for the protein to be expressed 
is cloned into SFV plasmid that serves as template for recombi- 
nant mRNA in vitro synthesis. The resulting recombinant 
mRNA carries the viral replicase gene and the foreign coding 
sequence under the viral subgenomic promoter. When intro- 
duced into cells, the recombinant mRNA allows expression of 
the viral replicase, which in turn drives efficient replication of 
the recombinant mRNA.  In this respect, a method allowing an 
efficient and functional mRNA transfer into cells would 
achieve the goal of mRNA transfection. Electroporation was 
shown to be efficient in transfecting the SFV recombinant 
mRNA into BHK21 cells [21], but is restricted to in vitro use. 
We provide here the first experimental evidence that N-t-butyl- 
N'-tetradecyl-3-tetradecyla minopropionamidine (diC14-amid- 
ine) forms a complex with self-replicating recombinant mRNA 
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capable of transfecting BHK21 cells with a high efficiency (vir- 
tually 100% of the cells were transfected). The diC 14-amidine 
mRNA complex has been characterized by sucrose gradient 
ultracentrifugation. Its protection against nuclease and trans- 
fection efficiency depends on the diC14-amidine/mRNA ratio. 
2. Materials and methods 
2.1. A4aterials 
Spel restriction enzyme, CTP, ATE GTP, UTP, m7G(5')ppp(5')G, 
RNasin, RNase-free DNase I, SP6 RNA polymerase, RNaseA, pro- 
teinase K, o-nitrophenyl-fl-D-galactopyranoside (ONPG), 5 bromo-4- 
chloro-fl-D-galactopyranoside (X-gal) and fl-galactosidase were pur- 
chased from Boehringer Mannheim. Spermidine and DTT were pur- 
chased from Sigma. [3H]DPPC, [c~-32P]UTP and 35S-labelled methionine 
were obtained from Amersham. BMV RNA and wheat germ extract 
were purchased from Promega. BHK21 medium, tryptose phosphate 
broth, glutamine, Hepes, penicillin-streptomycin and foetal calf serum 
(FCS) were obtained from Gibco-BRL. 
2.2. Plasmid DNA preparation and RNA synthesis 
The pSFV-LacZ plasmid was generously provided by Peter 
Liljestr6m (Sweden). It has been obtained by fusing the 8th codon of 
the E. eoli fl-galactosidase in frame with the initiating AUG of the 
capsid gene of SFV. The vector has been described in [21]. The plasmid 
DNA was prepared by alkaline lysis and cesium chloride-ethidium 
bromide equilibrium gradient centrifugation. For transcription, DNA 
was linearized by complete restriction digestion with SpeI at 2 U/Bg 
DNA for 2 h at 37°C (enzyme was added at the beginning of incubation 
and 1 h after). DNA was then phenol-extracted, thanol precipitated 
and finally resuspended in sterile water. Transcription was carried out 
as described [22] with the following modifications: a 100 ,ul reaction 
mixture was prepared to contain 80 mM Hepes-KOH (pH 7.5), 10 mM 
MgCI:, 2 mM spermidine, 40 mM DTT, 1.5 mM ATE 1.5 mM CTP, 
1.5 mM UTP, 1.5 mM m7G(5')ppp(5')G, 0.75 mM GTP, 1 U/BI RNa- 
sin, 100 Bg/ml DNA, 800 U/ml SP6 RNA polymerase. The mixture was 
incubated for 2 h at 37°C, then immediately mixed with RNase-free 
DNase I from bovine pancreas and incubated for a further 15 min at 
37°C. RNA was purified by chromatography using a G50 column 
(Pharmacia) according to manufacturer's in tructions and sterile water 
for the elution. Uncapped mRNA was prepared in a similar fashion, 
except that m7G(5')ppp(5')G was omitted and GTP concentration 
raised to 1.5 mM. Uncapped radioactive RNA was prepared as de- 
scribed above by adding 2 /,tl of [~-32P]UTP (800 Ci/mmol) to the 
reaction medium. 
2.3. Preparation of diC14-amidine su.spension 
DiC14-amidine was synthesized and vesicles were prepared as de- 
scribed [9] with the following modifications: 20 ¢tl of 50 mg/ml ethanolic 
solution was injected into 1 ml of 10 mM Hepes, 150 mM NaCI buffer 
(pH 7.2) under vortexing. The resulting suspension was used within the 
day of preparation. The mean size of d iCl4-amidine vesicles, prepared 
by ethanol injection method in 10 mM Hepes 150 mM NaCI buffer at 
pH 7.2 has been measured by laser light scattering: amean size of 300 
nanometers diameter was calculated. At high magnification and phase 
contrast microscopy, the vesicles look spherical. This vesicle suspension 
is stable at 4°C for several weeks and is not subject to oxidation. 
3H-labeled iC14-amidine liposomes were prepared as described above 
by adding [3H]DPPC (62 Ci/mmol) to the diC14-amidine thanolic 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
SSD1 0014-5793(96)00038-5 
A. El Ouahabi et al./FEBS Letters 380 (1996) 108 112 109 
solution (1 : 1000 [3H]DPPC/diC 14-amidine molar ratio) before vesicles 
formation. 
2.4. DiC14-amidin~mRNA complex characterization 
2.4.1. Sucrose gradient uhracentrifugation. 5 #g of uncapped 
mRNA (containing a fraction of 32P-radiolabeled mRNA to a total 
activity of 30,000 cpm) was mixed in 100 #1 of 10 mM Hepes, 150 mM 
NaC1 (pH 7.2) with various amounts of diC14-amidine liposomes (con- 
taining a fraction of 3H-labeled iC14-amidine liposomes to 100.000 
cpm) to give the desired diC14-amidine/RNA weight ratios (1:1, 2:1, 
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Fig. 1. Characterization of the diC14-amidine/mRNA complexes by 
sucrose gradient ultracentrifugation. Complexes were formed as de- 
scribed in section 2 and centrifuged on a 60 2% continuous ucrose 
gradient. [32p]RNA radioactivity (o) and [3H]lipid radioactivity (I) 
were measured along the gradient, Free mRNA (A). DiC14-amidine 
liposomes (B). 1 : 1 diCl4-amidine/mRNA weight ratio (C). 2 : 1 diCl4- 
amidine/mRNA weight ratio (D). 
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Fig. 2. Nuclease accessibility to the mRNA eomplexed with diCl4- 
amidine. Free or liposomes complexed mRNA were subjected to 
RNaseA digestion as described in section 2. Products were run on 
agarose gel and stained with ethidium bromide. Lanes are numbered 
from 1 to 14 from the left, Lane 1: control untreated mRNA. Lanes 2-5: 
digestion kinetics of free mRNA with 5, 15, 30 and 60 min incubation 
times, respectively. DiC14-amidine/mRNA complexes were digested in 
the same conditions. Lanes 68 :  diC 14-amidine/mRNA complexes with 
a weight ratio of 1 : 1 and 15, 30 and 60 min incubation times, respec- 
tively. Lanes 9-11: diC14-amidine/mRNA complexes with a weight 
ratio of2:1 and 15, 30 and 60 min incubation times, respectively. Lanes 
12-14: diC 14-amidine/mRNA complexes with a weight ratio of4:1 and 
15, 30 and 60 min incubation times, respectively. 
4:1 and 8 : 1). The suspension was mixed with 700 #l of 80% sucrose 
solution in 10 mM Hepes, 150 mM NaCI (pH 7.2) and layered under 
a 60%-2% continuous ucrose gradient. Tubes were centrifuged at 
100,000 × g for 16 h (4°C) in a Sorval AH-650 rotor. After centrifuga- 
tion, 200 #l fractions were sampled, mixed with 4 ml of Aquasol2 
scintillation cocktail (Dupont) and the [3H] (liposomes) and [32p] 
(mRNA) radioactivity counted. 
2.4.2. Nuclease protection assay. To investigate the accessibility of 
diC14-amidine complexed mRNA to the endonuclease RNase A, 3 #g 
of mRNA were diluted in 30 ,ul of 10 mM Hepes (pH 7.2) and mixed 
with 30 #1 of 10 mM Hepes (pH 7.2) containing 3, 6 or 12 #g of 
diC14-amidine liposomes. The mixture was incubated for 15 min at 
room temperature, mixed with 6 #1 of RNase A at 10 5 U/#I and 
incubated at 37 °C. After 15, 30 and 60 min, 22 #1 of mixture was 
removed and the digestion stopped by adding proteinase K at 2 mg/ml 
final concentration. All samples were mixed with SDS (1% final), load- 
ing buffer (glycerol 3% final, Bromophenol blue 0.25% final) and run 
on a 0.6% agarose gel in TBE (45 mM Tris-borate, 1mM EDTA, pH 
8) at 5 V/cm. Free mRNA was hydrolyzed as a control. 
2.5. mRNA tramfection of BHK21 cells 
BHK21 cells were obtained from the American Type Culture Collec- 
tion and grown in BHK21 medium supplemented with: 10% tryptose 
phosphate broth, 2 mM glutamine, 25 mM Hepes pH 7.2, penicillin- 
streptomycin (50 IU/ml and 50 UG/ml, respectively) and 5% FCS 
(complete medium). DiCl4-amidine mRNA complexes were prepared 
and transfected into BHK 21 cells essentially as described [9] with the 
following modifications: cells were plated in a 24 well culture dish at 
5 × 104 cells per well and grown overnight to reach approximately 70% 
confluency, mRNA~liC14-amidine complexes were prepared by sepa- 
rately diluting mRNA and diC14-amidine vesicles in 50 #1 of 10 mM 
Hepes, 150 mM NaC1 (pH 7.2). They were gently mixed in Polybutadi- 
ene Styrene tubes (Nunc Inc, Denmark) and incubated for 15 min at 
room temperature. The diC 14-amidine/mRNA mixture was then added 
to 300 #1 of medium in the absence or in the presence of serum. The 
cells were washed twice with medium without serum and incubated with 
complexes for 2 h tilting the plate every 15 min. The transfection 
medium was then removed and complete medium added. 
2.6. fl-Galactosidase assays 
2.6.1. Percentage of transfected cells. 24 h after transfection, the 
cells were washed twice with PBS ÷÷ (PBS with 1 mM Ca 2÷ and 1 mM 
Mg2+), fixed with methanol at -20°C for 5 min and washed 3times with 
PBS ÷+. Staining was performed in PBS containing 5 mM K4Fe(CN)6, 
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5 mM K3Fe(CN)6, 2 mM MgC12 and 1 mg/ml 5-bromo-4-chloro-fl-D- 
galactopyranoside (X-gal) for 4 h to overnight at 37°C. To determine 
the percentage of transfected cells, the blue stained cells were counted 
in 5 randomly chosen visual fields under the microscope and the mean 
was calculated. This number of cells was then divided by the number 
of cells contained in the observed field. 
2.6.2. Total fl-galaetosidase expression in transfeeted cells. 24 h after 
transfection, the cells were washed twice with PBS, overlayered with 
200 /ll of PBS, harvested and transferred to Eppendorf tubes and 
centrifuged for 2 min. The pellets were resuspended in 100,ul of 250 m M 
Tris (pH 7.8) and cells were lysed with three freeze-thawing cycles. 
Lysates were diluted in 100 mM sodium phosphate buffer, pH 7.5 and 
10/11 were mixed with 90/~1 sodium phosphate buffer (100 raM, pH 7.5) 
containing 1 mM MgCI2, 45 mM fl-mercaptoethanol and 1 mg/ml 
o-nitrophenyl-fl-D-galactopyranoside (ONPG) in a 96 well microtiter 
plate. A standard curve was obtained in parallel using purified fl- 
¢ 
g 
E 
0 
"6 
e l  
! 
o 
g 
3 
700 
600 
SO0 
400 
300 
200 
100 
0 
!:1 2:1 4:! 8:1 
dlCl4-emldlne/RNA reties (w:w) 
galactosidase ranging between 2.5 and 0.02 U per well. The reactions 
were carried out at 37°C for 1 to 2 h, stopped by adding 170 f l  of 
1 M Na2CO3 and absorbance was measured at 405 nm in a microtiter 
plate reader. 
2. 7. In vitro RNA translation 
BMV (Brome Mosaic Virus) mRNA was chosen because of its high 
translation efficiency in a cell-free translation system. BMV mRNA was 
in vitro translated in a 25 H1 reaction mixture containing 12.5 ,ul wheat 
germ extract, 130 mM potassium acetate, 1 U/H1 RNasin, 2 HI amino 
acid mixture, 1.5 f l  35S-labelled methionine and 1 fig mRNA or 1 pg 
mRNA complexed with diC 14-amidine. The reaction mixture was then 
incubated for 20 min at 25 °C. Recombinant SFV-LacZ mRNA was 
translated the same way. To quantify the radioactivity associated with 
newly synthesized polypeptides, reaction mixtures were diluted in 800 
f l  of water, precipitated with 30% TCA (final), filtrated on nitrocellu- 
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Fig. 3. Panels A and B: 105 BHK21 cells were transfected with 100 ng offl-galactosidase (fl-gal) recombinant mRNA and increasing amounts of lipids 
(see section 2) in 24-well plates in duplicates. A: cells were homogenized and total fl-gal activity quantified using the ONPG assay. The fl-gal activity 
was converted to an absolute level offl-gal protein per well using the fl-gal standard curve prepared in parallel. B: cells were in situ stained using 
the X-gal reagent and the percentage of positives cells counted. Data shown represent a typical result of the mean of 3 independent experiments. 
Panel C: effect of diC14-amidine/mRNA ratio on the percentage of transfected cells at higher mRNA dose. BHK21 cells (105) were transfected with 
500 ng mRNA and increasing amounts of diCl4-amidine. The percentages of transfected cells were plotted as a function of diC14-amidine/mRNA 
weight ratio. The experiment was repeated at different imes. Panel D: effect of mRNA dose on the percentage of transfected cells. BHK21 cells were 
transfected with complexes formed at constant diC14-amidine/mRNA weight ratio (2 : 1 ) and increasing amount o fmRNA (0.5~ fg). The percentages 
of transfected cells were plotted as a function of the mRNA quantity used for transfection. 
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lose filters and washed to remove unincorporated labeled methionine. 
The filters were dried and counted for radioactivity in Ecoscint O 
scintillation liquid (National Diagnostics). 
3. Results and discussion 
3.1. mRNAldiC14-amidine complex characterization 
Fig. 1 shows that in a continuous 60 to 2% sucrose gradient, 
free mRNA (Fig. 1A) was found in the bottom of the gradient 
whereas free diC14-amidine (Fig. 1B) migrated at the top. 
Mixed at 2:1 weight ratio prior to centrifugation, diC14-amid- 
ine and mRNA migrated at an intermediate density revealing 
complete association (Fig. 1D). At a 1:1 diC14-amidine/ 
mRNA weight ratio (Fig. 1C), two populations of free and 
diC14-amidine-associated mRNA could be separated. The 
single homogenous peak corresponding to mRNA-associated 
diC 14-amidine provides evidence of a homogenous population 
of complexes. At 4:1 and 8:1 diC14-amidine/mRNA weight 
ratios, the amount of material detectable in the gradient was 
too low to be measured (data not shown) mainly because of 
strong adhesion to the centrifuge tube walls. 
3.2. Nuclease accessibility to the diC14-amidine-complexed 
mRNA 
mRNA-diC14-amidine complexes and free mRNA were ex- 
posed to RNaseA. Free mRNA was completely degraded 
within 5 min incubation (Fig. 2, lanes 2 5). mRNA complexed 
with diC14-amidine at a l ipid/mRNA weight ratio of 1 : 1 was 
partially accessible to the enzyme (Fig. 2, lanes 6-8). Increasing 
the diC14-amidine to mRNA ratio above 2:1 fully protected 
the mRNA from hydrolysis (Fig. 2, lanes 9-14). Pre-incubation 
of the RNase with increasing amounts of diC14-amidine fol- 
lowed by addition of mRNA leaded to complete degradation 
of the mRNA indicating that diC 14-amidine is not an inhibitor 
of the RNase (data not shown). 
3.3. Optimization of the transfection protocol 
The percentage of transfected cells and the total fl-galactosi- 
dase expression were measured at several diC14-amidine! 
mRNA ratios using 100 ng mRNA per 105 cells, both parame- 
ters were shown to increase with the diC14-amidine/mRNA 
ratio to reach a plateau at a 4:1 ratio (Fig. 3A,B). 
Increasing the amount of mRNA from 100 ng to 500 ng to 
transfect the same amount of cells (105) enhanced the percent- 
age oftransfected cells by a factor of 4 to 5 at all diC14-amidine/ 
mRNA weight ratios, except at the highest ratio (8:1) corre- 
sponding to a total amount of 4 pg diC14-amidine (Fig. 3C). 
The lower efficiency at the 8 : 1 ratio could be associated to the 
cytotoxicity of diC14-amidine at high doses. It can however be 
controlled. Indeed, Fig. 3D shows that the transfection effi- 
ciency depends both on the mRNA dose and the diC14-amid- 
ine/mRNA ratio. With a 2 : 1 ratio and 2/.tg of mRNA,  about 
90 % of cells were transfected although 4 pg of diC14-amidine 
were used. It should be mentioned that the presence of serum 
in the transfection medium did not affect the transfection effi- 
ciency in these conditions. 
3.4. In vitro translation experiments" 
Little is known about he mRNA accessibility o the transla- 
tion machinery after its complexion with a cationic amphiphile. 
This point is very important to help discriminate between two 
possible pathways for transfection mechanism: entry of the 
complex in the cytoplasm or dissociation of the complex after 
initial contact with the membrane. Here, we have tried to eval- 
uate the availability of mRNA for in vitro translation after 
complexion with diC14-amidine. The mRNA of BMV (Brome 
Mosaic Virus) was used instead of recombinant SFV-LacZ 
mRNA since the later gives lower in vitro translation efficiency. 
This is probably due to the fact that SFV-LacZ mRNA is a long 
(about 9 kb), in vitro capped mRNA whereas BMV RNA is a 
mixture of short mRNA, efficiently capped in BMV infected 
cells. As a consequence, the stability and translation efficiency 
of SFV-LacZ mRNA is lower. BMV mRNA was translated 
here in a cell-free translation system containing wheat germ 
extract. Pre-incubation of the BMV mRNA with diC14-amid- 
ine before addition to the reaction mixture reduced the transla- 
tion efficiency by a factor of 2 at a diC14-amidine/mRNA ratio 
of 2 : 1 and completely at a 4 : 1 ratio (Fig. 4). On the contrary, 
sequential addition of the same amount of diC 14-amidine and 
mRNA (to a final diC14-amidine/mRNA ratio of 4: 1) to the 
translation reaction mixture yielded no more than 50% inhibi- 
tion of translation efficiency. It is likely that mRNA binds 
competitively to liposomes and ribosomes, the uncomplexed 
mRNA being responsible for the residual translation activity. 
If diC14-amidine would act as an inhibitor of the translation 
machinery, a total inhibition of the translation efficiency would 
be observed regardless of sequential or preformed complex 
addition since diC 14-amidine concentration was kept constant. 
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Fig. 4. Effect of diC14-amidine complexion on the translation efficiency 
of the BMV mRNA. 1 pg mRNA was used in each case. mRNA was 
used alone (free mRNA), preincubated with 2 ,ug of diC14-amidine 
(complexes 2 : 1 ) or 4 pg of diC 14-amidine (complexes 4: 1 ) before being 
translated in vitro in a 25 pl reaction mixture as described in section 
2. In a control experiment, 4 ~tg of diC14-amidine were added to the 
reaction mixture before addition of the mRNA (first diC14-amidine 
then mRNA). The radioactivity associated with newly synthesized 
polypeptides was counted and the values obtained expressed as a per- 
centage of the free mRNA value (the free mRNA translation efficiency 
was considered as 100%) after subtraction ofthe background (obtained 
for a reaction carried out without mRNA). 
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These cell-free translation experiments demonstrate that 
complexion of mRNA by diC14-amidine strongly reduces its 
accessibility to the translation machinery. It is therefore highly 
probable that in the cell context, the complex dissociates, at 
least partly, after its initial interaction with the cell membrane 
in order to make the mRNA available for efficient ranslation. 
Where and how this process takes place is unknown but surely 
merits further investigation. 
In summary, we have developed a highly efficient mRNA 
transfection system using diC14-amidine containing liposomes 
which was previously used for successful DNA transfection [9]. 
DiC 14-amidine has been previously shown to form vesicles that 
have been characterized [23]. In transfection reagents described 
so far, the polar head group contained an amine function. We 
demonstrate here that addition of another basic moiety (amid- 
ine) may also result in high transfection activity. 
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